Summary
Agilent Technologies, Inc. announced on April 22, 2015, that its subsidiary, Dako Denmark A/S, has received a close-out letter from the U.S. Food and Drug Administration (FDA) regarding a warning letter issued on August 21, 2013. The FDA has evaluated Dako's corrective actions related to compliance with current Good Manufacturing Practices (cGMP) at its Glostrup facility and has indicated that the violations appear to have been addressed. This development is a significant positive for Agilent, as it resolves a long-standing regulatory issue that could have impacted its operations and reputation.
Key Highlights
- 1Agilent's subsidiary, Dako Denmark A/S, received an FDA close-out letter for a prior warning letter.
- 2The FDA has evaluated Dako's corrective actions regarding cGMP compliance at its Glostrup facility.
- 3The FDA indicated that the violations cited in the August 21, 2013 warning letter appear to have been addressed.
- 4The FDA will continue to assess the adequacy and sustainability of corrective actions in future inspections.
- 5The company issued a press release on April 22, 2015, to announce this resolution.
- 6The information furnished in this report is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act.
Frequently Asked Questions
The close-out letter signifies that the FDA believes Agilent's subsidiary, Dako Denmark A/S, has adequately addressed the cGMP compliance issues at its Glostrup facility, resolving a prior warning letter. This reduces regulatory risk and potential operational disruptions for Agilent.
The FDA has stated that the violations 'appear to have been addressed.' However, the FDA will assess the adequacy and sustainability of these corrective actions in future inspections, meaning ongoing vigilance and compliance will be required.
The original FDA warning letter, dated August 21, 2013, concerned violations related to compliance with current Good Manufacturing Practices (cGMP) of the Quality System Regulations at Dako's Glostrup facility.
More information is available in the press release dated April 22, 2015, which is included as Exhibit 99.1 to this 8-K filing. Investors should note that the information furnished in this report is not considered 'filed' under Section 18 of the Securities Exchange Act.